This Forum brings together forward-thinking investors and a hand-selected group of high-potential startups for focused, insight-driven presentations.
Each company delivers a 5-minute presentation with Q&A, designed to surface meaningful discussion, validate opportunity, and accelerate engagement.
The program also features updates from select alumni companies, offering a clear view into post-Forum progress, milestones achieved, and future direction.
Where innovation meets traction—and relationships turn into outcomes.
QuantaPro enables oncologists to determine—early and in real time—whether chemotherapy will work, using a single drop of blood. Beginning with the ERCC1 chemo-resistance test, the company addresses a long-standing clinical blind spot in oncology while building a scalable, high-margin proteomic testing platform that will expand to other chronic diseases.
Pharma in silica’s precision chemotherapy attacks solid tumors while sparing patients painful, maiming and costly adverse effects imposed by current chemo. OpPacli™ is fifteen months to FDA Phase Ib/IIa 515(b)(2) clinical trial against NSCLC. In 2028, the nanocarrier platform will enable pharmas to capture the chemo drugs US$ 25B market.